IP Library Granted Patent US 8,147,532
Granted Patent B2
US 8,147,532 · App. 12/256,197 · Granted Apr 3, 2012

Determining patient-specific vapor treatment and delivery parameters

Assignee: Uptake Medical Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,147,532
App. No.
12/256,197
Granted
Apr 3, 2012
Kind
B2
Abstract

Methods and systems for determining patient specific treatment parameters for delivering vapor to the lung to treat lung tissue. In some embodiments vapor is delivered to the lung to cause coagulative necrosis, inducing fibrosis and thereby reducing the volume of at least one segment of the lung. The delivery parameters can be adjusted depending on the desired degree of injury to be induced in the lung tissue.

Claims (20)

1. A method of applying energy to tissue of a patient's lung to reduce the volume of the lung, the method comprising:

identifying at least one region of lung including the lung tissue to be treated;

inserting a delivery device into the lung region;

delivering vapor through the delivery device to the lung tissue to be treated at a dose between about 5 calories/gram to about 40 calories/gram, wherein the vapor undergoes a phase change to liquid, and energy released during the phase change is transferred to the lung tissue to injure the tissue.

2. The method of claim 1 wherein the region is a lung segment or sub-segment.

3. The method of claim 1 further comprising heating the vapor to at least 100° C. before delivering the vapor.

4. The method of claim 1 wherein the dose delivered causes the lung volume to be reduced over a period of about 4 to about 8 weeks.

5. The method of claim 1 wherein the dose delivered causes the lung volume to be immediately reduced from shrinking and or denaturing of collagen.

6. The method of claim 1 wherein the energy transferred to the tissue causes coagulative necrosis of the lung tissue.

7. The method of claim 6 wherein the coagulative necrosis is followed by fibrosis to effectively reduce the volume of the lung region.

8. The method of claim 6 wherein the energy transferred to the tissue causes substantially no thermal fixation.

9. The method of claim 1 wherein delivering the vapor comprises delivering the vapor at a flow rate of between about 20 calories/second to about 200 calories/second.

10. The method of claim 1 wherein delivering the vapor comprises delivering the vapor for a duration of between about 2 seconds to about 30 seconds.

11. The method of claim 10 wherein delivering the vapor comprises delivering the vapor for a duration between about 4 and about 10 seconds.

12. The method of claim 1 further comprising generating the vapor in a generator disposed outside of the patient.

13. The method of claim 1 wherein delivering comprises exposing the lung tissue to the vapor.

14. The method of claim 1 wherein the dose is between about 5 cal/g and about 20 cal/g.

15. The method of claim 1 wherein the dose is between about 5 cal/g and about 10 cal/g.

16. The method of claim 1 wherein the dose is between about 20 cal/g and about 40 cal/g.

17. The method of claim 1 wherein the delivering step comprises ablating microvasculature in the lung tissue.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2016
From: UPTAKE MEDICAL CORP.
To: UPTAKE MEDICAL TECHNOLOGY INC.
Reel/Frame 039388/0053 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2009
From: BARRY, ROBERT L.; CRAN, BRIAN; HENNE, ERIK; REDDY, DANIEL; CORCORAN, DEAN
To: UPTAKE MEDICAL CORP.
Reel/Frame 022859/0723 →
Continuity (2)
Provisional Application 60981701 · Oct 22, 2007
Related Publication 20090138001A1 · May 28, 2009